Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human DR4 Antibodies:
anti-Mouse (Murine) DR4 Antibodies:
anti-Monkey DR4 Antibodies:
Go to our pre-filtered search.
study involving a relatively large sample size showed that TNFRSF10 eQTL (show EQTN Antibodies) SNPs within lncRNAs might influence both hepatocellular carcinoma development and HBV infection
Study investigated the association between colorectal cancer and polymorphisms in TRAIL and DR4 (show HLADRB4 Antibodies) gene in Pakistani patients; TRAIL gene 1595 C>T genotypes percentage in colorectal cancer patients was statistically non-significant; for DR4 (show HLADRB4 Antibodies) A1322G, homozygous GG genotype was 36% in the patients and in controls: there was statistically insignificant difference (p> 0.05).
TRAIL genetic polymorphisms do not contribute, but DR4 (show HLADRB4 Antibodies) polymorphisms may contribute to susceptibility to head and neck cancer in Pakistani population.
The structure of death receptor 4 (DR4) in complex with TNF-related apoptosis-inducing ligand (TRAIL (show TNFSF10 Antibodies)) has been determined at 3 A resolution and compared with those of previously determined DR5 (show TNFRSF10B Antibodies)-TRAIL complexes.
LOC389641 promotes pancreatic ductal adenocarcinoma progression and increases cell invasion by regulating E-cadherin (show CDH1 Antibodies) with the possible involvement of TNFRSF10A (show TNFRSF10A Antibodies).
Results showed DR4 (show HLADRB4 Antibodies) promotor methylation and low protein expression level in patients with lung squamous carcinoma which correlated with the prognosis of the disease.
evaluate the role of polymorphisms of tumor necrosis factor (show TNF Antibodies)-related apoptosis-inducing ligand (TRAIL) and death receptor (DR4 (show HLADRB4 Antibodies)) genes in bladder cancer susceptibility
Studied an array of TRAIL-R1 and TRAIL-R2 (show TNFRSF10B Antibodies) specific variants on pancreatic cancer cells.
Genetic variation of TRAIL-R1 rs4242392 is linked with response to interferon (show IFNA Antibodies)-based therapy for hepatitis C virus infection, and genetic variation IFN-gamma (show IFNG Antibodies) rs2069707 is associated with natural clearance of hepatitis C virus infection.
The rs13278062 polymorphism of the DR4 (show HLADRB4 Antibodies) gene not only can confer an increased risk for crohn disease, but may also influence the location of the lesions and the disease behaviors.
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL), and thus transduces cell death signal and induces cell apoptosis. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.
TNF-related apoptosis-inducing ligand receptor 1
, TRAIL receptor 1
, cytotoxic TRAIL receptor
, death receptor 4
, tumor necrosis factor receptor superfamily member 10A
, tumor necrosis factor receptor superfamily member 10a variant 2